EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
+17.69%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$3.79B
AUM Growth
+$3.79B
(+22%)
Cap. Flow
+$279M
Cap. Flow
% of AUM
7.35%
Top 10 Holdings %
Top 10 Hldgs %
76.38%
Holding
68
New
9
Increased
11
Reduced
6
Closed
16
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$114M |
| 2 |
Sarepta Therapeutics
SRPT
|
$75.7M |
| 3 |
Galapagos
GLPG
|
$61.5M |
| 4 |
Revolution Medicines
RVMD
|
$49.4M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
$45.7M |
Top Sells
| 1 |
Janux Therapeutics
JANX
|
$40.2M |
| 2 |
Kymera Therapeutics
KYMR
|
$23.6M |
| 3 |
Adicet Bio
ACET
|
$20.5M |
| 4 |
Dyne Therapeutics
DYN
|
$17.1M |
| 5 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$10.3M |
Sector Composition
| 1 | Healthcare | 99.92% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Prothena Corp
PRTA
$441M
| $791M | 19.38% | 11,584,280 | – | – |
|
2
Apellis Pharmaceuticals
APLS
$3.48B
| $497M | 12.17% | 5,451,647 | – | – |
|
|
3
Sarepta Therapeutics
SRPT
$1.78B
| $419M | 10.27% | 3,660,798 +661,345 | +22% | +$75.7M |
|
|
4
Galapagos
GLPG
$2.07B
| $234M | 5.73% | 5,756,268 +1,511,623 | +36% | +$61.5M |
|
|
MORF
5
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $221M | 5.4% | 3,846,964 -2 | -0% | -$115 |
|
|
6
Revolution Medicines
RVMD
$7.1B
| $193M | 4.72% | 7,198,700 +1,846,517 | +35% | +$49.4M |
|
7
AnaptysBio
ANAB
$569M
| $153M | 3.75% | 7,521,024 | – | – |
|
8
Acadia Pharmaceuticals
ACAD
$4.38B
| $143M | 3.52% | 5,991,479 | – | – |
|
9
Xencor
XNCR
$580M
| $132M | 3.23% | 5,282,516 | – | – |
|
10
Zymeworks
ZYME
$1.12B
| $116M | 2.84% | 13,437,473 +3,350,000 | +33% | +$28.9M |
|
|
BPMC
11
DELISTED
Blueprint Medicines
BPMC
| $114M | 2.78% | +1,798,300 | New | +$114M |
|
12
Arvinas
ARVN
$568M
| $99.7M | 2.44% | 4,017,788 +300,000 | +8% | +$7.45M |
|
|
SWTX
13
DELISTED
SpringWorks Therapeutics
SWTX
| $90.7M | 2.22% | 3,460,208 | – | – |
|
14
Kura Oncology
KURA
$686M
| $61.4M | 1.51% | 5,806,871 -831,500 | -13% | -$8.8M |
|
15
Relay Therapeutics
RLAY
$619M
| $52.3M | 1.28% | 4,163,824 | – | – |
|
|
16
Jazz Pharmaceuticals
JAZZ
$7.75B
| $45.7M | 1.12% | +368,411 | New | +$45.7M |
|
17
Voyager Therapeutics
VYGR
$186M
| $44.1M | 1.08% | 3,851,507 | – | – |
|
|
CNTA
18
Centessa Pharmaceuticals
CNTA
$2.25B
| $34.8M | 0.85% | 5,618,779 | – | – |
|
19
Edgewise Therapeutics
EWTX
$1.51B
| $27.1M | 0.66% | 3,493,194 | – | – |
|
20
Oric Pharmaceuticals
ORIC
$994M
| $26.5M | 0.65% | 3,418,068 | – | – |
|
21
Atea Pharmaceuticals
AVIR
$267M
| $26.2M | 0.64% | 6,995,861 +811,000 | +13% | +$3.03M |
|
22
Nuvation Bio
NUVB
$1.02B
| $25M | 0.61% | 13,896,543 | – | – |
|
23
Alector
ALEC
$238M
| $24.4M | 0.6% | 4,056,548 | – | – |
|
24
Crinetics Pharmaceuticals
CRNX
$2.92B
| $24M | 0.59% | 1,330,263 | – | – |
|
25
Allogene Therapeutics
ALLO
$251M
| $22.3M | 0.55% | 4,488,200 | – | – |
|